← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT06789601

Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository

Trial Parameters

Condition Malignancy
Sponsor Brigham and Women's Hospital
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 100
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2025-06-17
Completion 2027-08-31
Interventions
Informatics system for eligibility monitoringStandard eligibility monitoring

Brief Summary

Immunotherapies have improved cancer outcomes, but have a unique profile of immune-related adverse events (irAEs). Biorepositories have been established to collect data and samples to help improve our understanding of irAEs, however identifying patients who are eligible for these biorepositories in a timely fashion can be challenging. The goal of this study is to determine if an informatics system for automated irAE detection can improve registration to a prospective irAE biorepository (NCT04242095). The informatics system automatically "reads" participants' electronic health records (EHRs) and determines whether that patient may be experiencing an irAE. The main questions it aims to answer are: * Is it feasible to implement an informatics system for daily analysis of EHR data to detect irAEs? * Does the automated irAE detection system improve registration rates to an irAE biorepository at our institution following an eligible irAE? Researchers will compare standard irAE monitoring to informatics-assisted irAE monitoring to see if using the informatics system increases the registration rate and improves data entry efficiency and quality. Participants will: * Be randomly assigned to standard monitoring or informatics-assisted monitoring for irAE detection. * Have their EHR reviewed to collect demographic, medical, and cancer treatment history. * Be monitored for irAEs through daily automated analysis of their EHR data for up to 12 months or until registration in the biorepository.

Eligibility Criteria

Inclusion Criteria: * Received or receiving a regimen containing one or more immuno-oncology therapeutics

Related Trials